Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Genvec's Capital Expenditure for the
three
months ended in Mar. 2017 was $-0.09 Mil. Its Revenue for the
three
months ended in Mar. 2017 was $0.11 Mil.
Hence, Genvec's Capex-to-Revenue for the
three
months ended in Mar. 2017 was 0.76.
Genvec Capex-to-Revenue Historical Data
The historical data trend for Genvec's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genvec's Capex-to-Revenue
For the Biotechnology subindustry, Genvec's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genvec's Capex-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genvec's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Genvec's Capex-to-Revenue falls into.
Genvec Capex-to-Revenue Calculation
Genvec's Capex-to-Revenue for the fiscal year that ended in Dec. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genvec (NAS:GNVC) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Genvec Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of Genvec's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GNVC has been successfully added to your 